Psychiatric Times
JULY 1, 2025
Manufacturers of extended-release stimulants that currently do not have a Limitation of Use section in the labeling will be required to add one about this risk, and manufacturers that do already have a Limitation of Use section will be required to revise the labeling to ensure consistent messaging.
Psychiatric Times
JUNE 23, 2025
2 In a press release, NRx Pharmaceuticals said NRX-100 is well positioned for this designation, citing its alignment with national health priorities such as addressing the mental health crisis, innovating treatment for unmet needs, and enhancing domestic drug manufacturing. 1 NRx appears to be committed to the mental health space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 30, 2025
A recently filed patent on its preservative-free manufacturing process may further support market exclusivity. Additionally, the company plans to file a citizen petition with the FDA to withdraw preservative-containing forms of ketamine, citing concerns about benzethonium chloride toxicity.
Mad in America
OCTOBER 18, 2023
Dhar: Is this what inspired you to create the “documentary” for ‘Motivational Deficiency Disorder’ and the April Fool piece in BMJ along with it? A recent real-life example of this kind of advertising was for binge-eating disorder , and Monica Seles was the celebrity they used. What was that about?
Mad in America
DECEMBER 30, 2023
Kids—especially teenage girls—are presenting with self-described Tourette’s, eating disorders, autism, and dissociative identity disorder (DID)—but suddenly, and in a way that doesn’t match how these diagnoses have previously been identified.
Expert insights. Personalized for you.
98 
Let's personalize your content